Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes
Purpose of Review
The purpose of this review is to correlate predictions based on pre-clinical data with outcomes from clinical trials that examine the effects of incretin-based diabetes treatments on the kidney. The incretin-based treatments include agonists of the glucagon-like peptide 1 receptor (GLP-1R) and inhibitors of the enzyme, dipeptidyl peptidase-4 (DPP-4). In addition, what is known about the incretin-based therapies will be compared to what is known about the renal effects of SGLT2 inhibitors.
Large-scale clinical trials have shown that SGLT2 inhibitors reduce albuminuria and preserve estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy. A concise and plausible hemodynamic mechanism is supported by pre-clinical research on the physiology and pharmacology of SGLT2. Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria but have not shown beneficial effects on eGFR. Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s). But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
There may be salutary effects of incretin-based treatments on the diabetic kidney, but the system is complex and not amenable to simple explanation or prior prediction. This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
KeywordsDPP-4 GLP-1 SGLT2 Glomerular filtration Tubular reabsorption Albuminuria
The authors work was supported by the National Institutes of Health (R01DK56248, R01DK112042, R01DK106102, P30DK079337), the Department of Veterans Affairs, and investigator-initiated research grants by Bristol-Myers Squibb, Merck, and Boehringer Ingelheim.
Compliance with Ethical Standards
Conflict of Interest
Dr. Thomson has received research support from Merck and Pfizer. Dr. Vallon has served as a consultant and received honoraria from Boehringer Ingelheim, Intarcia Therapeutics, Janssen Pharmaceutical, Eli Lilly, and Merck, and received grant support for investigator-initiated research from Boehringer Ingelheim, Astra-Zeneca, Fresenius, Janssen, and Bayer.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 2.Mogensen CE. Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus. Scand J Clin Lab Invest. 1971, 28:91–100>.Google Scholar
- 15.Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016: 375:323–334.Google Scholar
- 17.Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;2014(155):1280–90.Google Scholar
- 19.Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 014:35:992– 1019.Google Scholar
- 24.Rieg T, Gerasimova M, Murray F, Masuda T, Tang T, Rose M, et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol. 2012;303:F963–71.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.• Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Diamant M, Joles JA, et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab. 2016, 18:178–85. Study showing acute renal vasodilation in response to acute GLP-1R agonist in non-diabetic humans. Findings are analogous to earlier animal studies (ref. 23). Google Scholar
- 29.• Tonneijck L, Smits MM, MHA M, Hoekstra T, Kramer MHH, Danser AHJ, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016, 59:1412–21. Study from same laboratory as ref. 28 showing acute decline in proximal reabsorption but no renal vasodilation in response to acute GLP-1R agonist in diabetic humans. Putative explanation for lack of renal vasodilation in diabetics is that the tubular effect led to activation of TGF to offset the direct vasodilatory response seen in ref. 28. Google Scholar
- 32.Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complicat. 2014;28:399–405.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Guyton AC, Lohmeier TE, Hall JE, Smith MJ, Kastner PR. The infinite gain principle for arterial pressure control by the kidney-volume-pressure system. In: Sambhi MP, editor. Fundamental fault in hypertension. Developments in cardiovascular medicine. Dordrecht: Springer; 1984. p. 36.Google Scholar
- 35.Shah, Z., Pineda, C., Kampfrath, T., Maiseyeu, A., Ying, Z., Racoma, I., ... & Villamena, F. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc Pharmacol 2011:55: 2–9.Google Scholar
- 37.Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Food and Drug Administration, December 2008 ttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
- 39.Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017: 377:644–657.Google Scholar
- 40.• Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, et al. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. Am J Kidney Dis. 2015;66:441–9. Patient-level data from combined linagliptin trials showing DPP-4 treatment improves a composite renal endpoint. It was not mentioned in the abstract that the result was driven by lower incident albuminuria, not by preservation of eGFR.CrossRefPubMedGoogle Scholar
- 41.• Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016, 375:1834–44. CVD outcome trial with GLP-1R agonist showing lower incidence of albuminuria, but lacking power to study impact on renal function. Google Scholar
- 43.• Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017, 377:839–48. Secondary publication from CVD trial of another GLP-1R agonist showing lower incidence of albuminuria, but lacking power to study impact on renal function.Google Scholar
- 44.• Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369:1317–26. CVD trial of DPP-4 inhibitor, saxagliptin, reporting salutary effect on proteinuria but no impact on eGFR.Google Scholar
- 46.• Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, et al. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes Obes Metab. 2017, 19:1587–93. Ancillary data from CVD trial of DPP-4 inhibitor, sitagliptin, showing no effect on eGFR over 4-year period. However, the rate of decline in eGFR in both treatment and placebo groups was negligible.Google Scholar
- 47.• Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017, 19:1610, 1619. Only randomized DPP-4 inhibitor trial designed with primary renal endpoint. In this trial, linigliptin had no effect on albuminuria or eGFR.Google Scholar
- 48.Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63:2120–31.CrossRefPubMedGoogle Scholar